Migration Contributes to Flat HBV Infection Prevalence Rate in U.S.

This article originally appeared here.
Share this content:
Migration Contributes to Flat HBV Infection Prevalence Rate in U.S.
Migration Contributes to Flat HBV Infection Prevalence Rate in U.S.

WEDNESDAY, Aug. 12, 2015 (HealthDay News) -- The prevalence of chronic hepatitis B virus (HBV) infection has remained constant since 1999, according to a study published online Aug. 6 in Hepatology.

Henry Roberts, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues sought to determine the prevalence of HBV infection among non-institutionalized individuals aged 6 years and older. They examined the prevalence of antibody to hepatitis B core antigen (anti-HBc), hepatitis B surface antigen, and antibody to hepatitis B surface antigen over three periods: 1988 to 1994, 1999 to 2009, and 2007 to 2012.

The researchers found that for 2007 to 2012, 3.9 percent had anti-HBc. Since 1999, the overall prevalence of chronic HBV infection remained constant at 0.3 percent; the prevalence among non-Hispanic blacks was two- to three-fold greater than that seen in the general population. During 2011 to 2012, an estimated 3.1 percent of non-Hispanic Asians were chronically infected with HBV. Since 1999, there was a 16 percent increase in the adjusted prevalence of vaccine-induced immunity, and there was an increase in the number of persons, mainly young, with serologic evidence of vaccine protection from HBV infection, from 57.8 to 68.5 million.

"Despite increasing immune protection in young persons vaccinated in infancy, an analysis of chronic hepatitis B prevalence in racial and ethnic populations indicates that during 2011 to 2012 there were 847,000 HBV infections (which included ~400,000 non-Hispanic Asians) in the non-institutionalized U.S. population," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Panel Has Tie Vote on New Type 1 Diabetes Drug

FDA Panel Has Tie Vote on New Type ...

Zynquista is a once-daily pill meant to help type 1 diabetes patients manage their blood glucose levels

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

FDA Investigating Paclitaxel-Coated Balloons, Paclitaxel-Eluting Stents

Investigation triggered by meta-analysis showing possible increased mortality in PAD patients at 2 years

Frailty Could Increase Susceptibility for Dementia

Frailty Could Increase Susceptibility for Dementia

Authors say frailty should be considered in clinical care, management of Alzheimer dementia

is free, fast, and customized just for you!




Already a member?

Sign In Now »